Research programme: antibacterials - Microbiotix/Millenia Hope Biopharma

Drug Profile

Research programme: antibacterials - Microbiotix/Millenia Hope Biopharma

Alternative Names: Antibacterials research programme - antibacterials - Microbiotix/Avance Pharma

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Microbiotix; Millenia Hope Biopharma
  • Class Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Bacterial infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Bacterial-infections in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Bacterial-infections in Canada
  • 21 Feb 2006 Avance Pharma has been acquired and merged into Millenia Hope Biopharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top